Expert Ratings for Protagonist Therapeutics
Portfolio Pulse from Benzinga Insights
Protagonist Therapeutics (NASDAQ:PTGX) has received positive analyst ratings in the last quarter, with 3 bullish and 2 somewhat bullish ratings. The company has an average 12-month price target of $37.4, which has increased by 33.57% over the past month.
July 06, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings and increased price target for Protagonist Therapeutics indicate a positive outlook for the company, which could lead to increased demand for the stock and a potential increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100